8-K: Allogene Faces Patent Risk from Cellectis Lawsuit

Allogene Therapeutics disclosed a patent infringement lawsuit filed against its gene-editing technology licensor, Cellectis, which could impact Allogene's key product candidates.

Summary

• Factor Bioscience Inc. filed a complaint on September 26, 2025, against Cellectis S.A. and its affiliate Cellectis, Inc. in the United States District Court for the District of Delaware.
• The complaint alleges that Cellectis's TALEN-based gene-editing technology infringes three of Factor's U.S. patents related to gene-editing techniques, specifically Factor's patented mRNA TALEN technology.
• Factor claims Cellectis copied its technology, passed it off as its own, and entered into license agreements, including with Allogene Therapeutics, Inc., to capitalize on the alleged infringement.
• AstraZeneca PLC and certain affiliates are also named as defendants, with Factor alleging direct infringement by AstraZeneca through the use of Cellectis's allegedly infringing TALEN technology.
• Cellectis notified Allogene on October 6, 2025, stating that it disputes Factor's claims and intends to vigorously defend against them.
• Allogene is not a direct party to this litigation but relies on the TALEN gene-editing technology licensed from Cellectis for certain allogeneic CAR T cell product candidates, including cema-cel and ALLO-316.
• Factor may choose to assert direct claims against Allogene as a commercial user of the disputed technology.

Sentiment

Score: 3

Explanation: The filing discloses a significant legal risk to Allogene's core technology platform, which could impact its product pipeline. While Allogene is not a direct defendant, its reliance on the disputed technology creates substantial uncertainty and potential for delays or increased costs.

Negatives

• A patent infringement lawsuit has been filed against Cellectis, Allogene's gene-editing technology licensor, alleging infringement of core technology.
• Allogene relies on the disputed TALEN technology for its key allogeneic CAR T cell product candidates, cema-cel and ALLO-316, creating significant operational and development risk.
• There is a potential for Factor Bioscience Inc. to assert direct claims against Allogene as a commercial user of the allegedly infringing technology.
• The lawsuit introduces uncertainty and potential delays for Allogene's product discovery, development, and commercialization efforts.

Risks

• Reliance on Cellectis's TALEN gene-editing technology, which is now subject to a patent infringement lawsuit, could materially limit revenue opportunities if the technology becomes unusable.
• Potential for Factor Bioscience Inc. to assert direct claims against Allogene as a commercial user of the disputed technology, leading to direct legal exposure and costs.
• Third-party claims of intellectual property infringement may prevent or delay Allogene's product discovery and development efforts and its ability to commercialize product candidates.
• Allogene may not be successful in obtaining or maintaining necessary rights to product components and processes for its development pipeline through acquisitions and in-licenses.

Future Outlook

Cellectis intends to vigorously defend against Factor's claims. Allogene's future product development, particularly for cema-cel and ALLO-316, could be impacted depending on the outcome of this litigation and whether Factor asserts direct claims against Allogene.

Management Comments

• Cellectis disputes Factor's claims and intends to vigorously defend against them.

Industry Context

The biotechnology and pharmaceutical industries heavily rely on intellectual property and licensing agreements for novel technologies like gene editing. Patent disputes are common and can significantly impact product development timelines and market access, especially for foundational technologies like TALEN. This highlights the inherent IP risks in developing cutting-edge therapies and the potential for legal challenges to disrupt strategic partnerships and product pipelines.

Legal Proceedings

• Factor Bioscience Inc. filed a complaint against Cellectis S.A. and its affiliate Cellectis, Inc. in the U.S. District Court for the District of Delaware on September 26, 2025.
• The complaint alleges infringement of three of Factor's U.S. patents relating to gene-editing techniques by Cellectis's TALEN-based gene-editing technology.
• AstraZeneca PLC and certain affiliates are also named as defendants, alleged to have directly infringed by using Cellectis's technology.
• Cellectis disputes the claims and intends to vigorously defend against them.
• Allogene is not a party to this litigation, but Factor may assert direct claims against Allogene as a commercial user of the disputed technology.

Stakeholder Impact

• Shareholders: Increased uncertainty and potential downside risk due to reliance on disputed technology; potential for delays in product development and commercialization; possible legal costs if Allogene becomes a direct defendant.
• Employees: Potential impact on research and development efforts related to CAR T cell product candidates.
• Customers (future): Potential delays in bringing cema-cel and ALLO-316 to market.
• Partners (Cellectis, Servier): Direct impact on Cellectis due to the lawsuit; potential indirect impact on Servier if their agreements are tied to the same technology.

Next Steps

• Cellectis will defend against Factor's claims in the United States District Court for the District of Delaware.
• Allogene will monitor the litigation and assess potential impacts on its product candidates and operations.

Key Dates

Recommendation

The patent infringement lawsuit against Cellectis, Allogene's gene-editing technology licensor, introduces substantial intellectual property risk to Allogene's key product candidates, cema-cel and ALLO-316. While Allogene is not a direct party, the potential for direct claims and the reliance on the disputed TALEN technology create significant uncertainty regarding future development and commercialization. Investors should hold and monitor the legal proceedings closely, as the outcome could materially impact Allogene's valuation and strategic trajectory.

Keywords

Allogene Therapeutics, Cellectis, Factor Bioscience, patent infringement, gene editing, TALEN, CAR T cell, cema-cel, ALLO-316, intellectual property, litigation, biotechnology, pharmaceutical